Oxford Pharmascience Group plc has signed a license agreement with Bayer Consumer Care AG (BYR.L,BAYRY.PK,BAYZF.PK) in Basel to allow them to manufacture a calcium and Vitamin D soft chew using the Company's OXP chew technology. Pursuant to the deal, Bayer is being awarded a ten year license to manufacture a calcium and vitamin D soft chew product.
Nigel Theobald, Chief Executive, Oxford Pharmascience Group Plc, commented: "Partnering with Bayer is further evidence of our credibility in commercialising our technology platforms with major pharmaceutical companies. This is our first commercial relationship with a major global pharmaceutical company and their commitment and interest in our technologies is further evidence that our new strategic direction is working."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.